Want to see CLGN full AI Analyst Report?
Collplant Holdings (CLGN) AI Stock Analysis
Collplant Holdings
(NASDAQ:CLGN)
The score is primarily held down by very weak financial performance (minimal/declining revenue, heavy losses, and sustained cash burn with equity erosion). Technicals are only neutral with the stock still well below its 200-day average, and valuation remains unattractive due to negative earnings and no dividend yield support.
Collplant Holdings (CLGN) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $7.71M
- Dividend Yield
- ―
- Average Volume (3M)
- 367.41K
- Price to Earnings (P/E)
- -0.4
- Beta (1Y)
- 0.07
- Revenue Growth
- -86.76%
- EPS Growth
- 16.63%
- Country
- US
- Employees
- 39
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Collplant Holdings Business Overview & Revenue Model
Company Description
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine enterprise operating across the United States, Canada, and Europe. The company primarily engages in the three-dimensional (3D) bioprinting of tissues and organs, alongside develo...
Collplant Holdings Earnings Call Summary
Despite significant advancements in preclinical programs and continued collaboration with AbbVie, the company experienced a sharp decline in annual revenue and increased net losses, presenting a mixed financial outlook.
Q4-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the CollPlant Biotechnologies Ltd. investor call, CEO Yehiel Tal and Deputy CEO Eran Rotem provided guidance centered on their regenerative medicine advancements, notably highlighting their proprietary photocurable dermal filler and regenerative breast implant programs. The dermal filler, aimed at a market valued at approximately $6.3 billion with a 10% CAGR, is currently in the preclinical phase, with plans to launch a clinical trial within two years. The regenerative breast implant program is progressing with preclinical testing of 250cc commercial-sized prototypes, showing promising results in tissue integration without complications. Financially, CollPlant reported a decrease in revenue from $11 million in 2023 to $515,000 in 2024, primarily due to a $10 million milestone payment from AbbVie in 2023. Despite a GAAP net loss of $16.6 million in 2024 compared to $7 million in 2023, the company maintains a stable cash position of $11.9 million as of December 31, 2024, not accounting for an additional $2 million payment from AbbVie, ensuring operational capability into the second quarter of 2026.
Collplant Holdings Financial Statement Overview
Summary
Overall fundamentals are very weak: revenue is very small and declining, profitability is deeply negative, and losses remain substantial. Cash flow is consistently negative with ongoing cash burn, while the balance sheet shows only moderate leverage but a sharply shrinking equity base that raises financing risk.
Income Statement
12Very NegativeBalance Sheet
38NegativeCash Flow
14Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 318.00K | 2.37M | 515.00K | 10.96M | 299.00K | 15.64M |
| Gross Profit | -1.66M | 624.00K | -2.15M | 7.87M | -1.18M | 13.64M |
| EBITDA | -11.52M | -10.56M | -15.55M | -5.91M | -15.81M | 1.05M |
| Net Income | -12.51M | -11.49M | -16.61M | -7.02M | -16.93M | 237.00K |
Balance Sheet | ||||||
| Total Assets | 7.20M | 10.79M | 18.71M | 34.13M | 37.77M | 51.22M |
| Cash, Cash Equivalents and Short-Term Investments | 2.95M | 5.95M | 11.91M | 26.67M | 29.65M | 43.30M |
| Total Debt | 2.66M | 2.85M | 3.08M | 3.16M | 2.91M | 3.61M |
| Total Liabilities | 4.25M | 4.70M | 5.25M | 5.79M | 5.49M | 6.10M |
| Stockholders Equity | 2.94M | 6.08M | 13.46M | 28.34M | 32.28M | 45.12M |
Cash Flow | ||||||
| Free Cash Flow | -11.70M | -9.45M | -14.58M | -3.72M | -14.97M | 1.07M |
| Operating Cash Flow | -11.61M | -9.42M | -14.09M | -2.76M | -13.70M | 2.50M |
| Investing Cash Flow | -8,883 | -27.00K | -539.00K | -1.16M | 28.92M | -31.56M |
| Financing Cash Flow | 2.45M | 3.10M | 9,000 | 1.11M | 1.87M | 38.76M |
Collplant Holdings Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLGN, the sentiment is Positive. The current price of 4.11 is above the 20-day moving average (MA) of 3.82, above the 50-day MA of 3.71, and below the 200-day MA of 5.05, indicating a neutral trend. The MACD of 0.11 indicates Negative momentum. The RSI at 55.04 is Neutral, neither overbought nor oversold. The STOCH value of 61.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLGN.
Collplant Holdings Risk Analysis
Collplant Holdings disclosed 81 risk factors in its most recent earnings report. Collplant Holdings reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksCollplant Holdings Peers Comparison
Overall Rating
PYPD56Neutral
DARE45Neutral- CLGN44Neutral
NRSN41Neutral
PASG41Neutral
SABS39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| PYPD | 56Neutral | $110.09M | -3.69 | -311.07% | ― | ― | 61.30% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| DARE | 45Neutral | $12.88M | -0.82 | -748.08% | ― | ― | ― |
| CLGN | 44Neutral | $7.71M | -0.44 | -215.58% | ― | -86.76% | 16.63% |
| NRSN | 41Neutral | $2.71M | -0.18 | 610.97% | ― | ― | ― |
| PASG | 41Neutral | $10.68M | -0.30 | -218.59% | ― | ― | 38.14% |
| SABS | 39Underperform | $300.26M | 0.87 | -6.74% | ― | -100.00% | 95.16% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CLGN | CollPlant Biotechnologies Ltd. | 4.11 | -17.79 | -81.23% | |
| DARE | Daré Bioscience | 0.65 | -1.19 | -64.67% | |
| PASG | Passage Bio, Inc. | 3.40 | -3.30 | -49.25% | |
| PYPD | PolyPid Ltd. | 5.46 | 1.67 | 44.06% | |
| SABS | Sab Biotherapeutics, Inc. | 3.12 | -0.06 | -1.89% | |
| NRSN | Neurosense Therapeutics Ltd. | 1.28 | -19.69 | -93.90% |
Collplant Holdings Corporate Events
CollPlant Names Eran Rotem CEO as Cost-Cutting Plan Ends Regenerative Medicine R&D
CollPlant Biotechnologies, an Israel-based biotechnology company focused on biofabrication materials, produces recombinant human collagen (rhCollagen) and rhCollagen-based bioinks for regenerative medicine and three-dimensional bioprinting applicatio...
CollPlant Subsidiary LightSolver Wins Israel Defense Ministry Deal for Photonic Computing
On October 29, 2026, CollPlant’s subsidiary LightSolver signed a paid multi-year framework agreement with the Israel Ministry of Defense’s Directorate of Defense Research & Development to develop and deliver its Laser Processing Unit...
CollPlant Biotechnologies Raises $3.7 Million in October Private Placement
On October 9, 2026, CollPlant Biotechnologies Ltd. entered into a securities purchase agreement with institutional investors for a private placement of ordinary shares, pre-funded warrants and ordinary warrants, with the offering closing on October 1...
CollPlant Raises $3.7 Million to Accelerate LightSolver Laser Supercomputing
On October 9, 2026, CollPlant Biotechnologies announced it had entered into definitive agreements for a $3.7 million private placement of ordinary shares and accompanying warrants, led primarily by existing investors. The deal, priced at about $3.74...
CollPlant’s LightSolver Files U.S. Patent to Expand Photonic Computing for Advanced Simulations
On October 6, 2026, CollPlant Biotechnologies announced that its subsidiary LightSolver filed a U.S. provisional patent application covering a new method to configure its programmable analog, all-optical laser processor for solving inhomogeneous boun...
CollPlant Deepens Photonic Computing Push with LightSolver Deal as Q2 Loss Narrows
On September 30, 2026, CollPlant reported second-quarter 2026 results showing GAAP revenues of $108,000, down from $179,000 a year earlier, and a GAAP net loss of $2.7 million, reflecting lower rhCollagen product sales and the absence of a prior-year...
CollPlant’s LightSolver Reports Major Photonic Computing Breakthrough in HPC Study
On September 24, 2026, CollPlant subsidiary LightSolver and Germany’s High-Performance Computing Center Stuttgart published joint research showing that LightSolver’s pure photonic Laser Processing Unit architecture can dramatically speed...
CollPlant Regains Nasdaq Bid Price Compliance, Shoring Up Dual Tech Strategy
On September 22, 2026, CollPlant Biotechnologies Ltd., a deep-tech and biotech firm, disclosed that it had regained compliance with Nasdaq’s minimum bid price rule after shares closed at or above $1.00 for ten consecutive sessions earlier in th...
CollPlant Highlights LightSolver Optical Computing Strategy in Updated September 2026 Presentation
On September 17, 2026, CollPlant Biotechnologies posted an updated corporate presentation highlighting its planned acquisition and commercialization of LightSolver, a developer of optical high-performance computing systems that use interacting lasers...
CollPlant Adds LightSolver Founder to Board After Closing Photonic Computing Acquisition
CollPlant Biotechnologies announced on September 4, 2026 that it has appointed Dr. Ruti Ben Shlomi, CEO and co-founder of LightSolver Ltd., to its Board of Directors following the closing of CollPlant’s acquisition of LightSolver. Her appointme...
CollPlant Closes LightSolver Acquisition, Expands Into Photonic Computing
On September 3, 2026, CollPlant Biotechnologies closed its acquisition of Israeli deep-tech firm LightSolver, marking its formal entry into the high-performance computing and photonics sectors. The deal, structured primarily in equity with an additio...
CollPlant Biotechnologies Implements 1-for-10 Reverse Share Split to Maintain Nasdaq Listing
CollPlant Biotechnologies announced that its board approved a one-for-ten reverse share split of its ordinary shares, following shareholder approval at an extraordinary general meeting on August 18, 2026. The reverse split will take effect when tradi...
CollPlant to Acquire LightSolver, Pivoting Into Photonic Supercomputing
CollPlant Biotechnologies Ltd., based in Rehovot, Israel, operates at the intersection of regenerative medicine and advanced high‑performance computing. In healthcare, it develops recombinant human collagen-based products for 3D bioprinting of...
CollPlant Shareholders Approve All Proposals at August 18 Extraordinary Meeting
On August 18, 2026, CollPlant Biotechnologies Ltd. held an Extraordinary General Meeting of Shareholders in Israel as part of its ongoing corporate governance processes. The meeting followed a formal notice issued on July 28, 2026 to investors pursua...
CollPlant Biotechnologies Bolsters Authorized Share Capital and Validates Resale Shares After July Private Placement
On August 6, 2026, CollPlant Biotechnologies filed a Form 6-K in the U.S. to report that its shareholders had previously approved, on July 29, 2026, a substantial increase in authorized share capital from 30 million to 500 million ordinary shares. Th...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 01, 2026